<DOC>
	<DOC>NCT00151827</DOC>
	<brief_summary>This is a study in hypertensive patients with mild to moderate renal impairment. The antihypertensive efficacy of olmesartan medoxomil is compared to losartan.</brief_summary>
	<brief_title>Olmesartan Medoxomil in Hypertension and Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<criteria>Mean sitting BP prior to randomization of 140180/90109 mmHg; Renal impairment prior to randomization of mild (50 ≤ CLcr ≥ 80 mL/min) to moderate (30 ≤ CLcr ≥50 mL/min) severity Malignant hypertension or sitting BP greater than 180/109 mmHg; Severe heart failure, severe renal disease; Recent history of myocardial infarction, stroke or transient ischemic attack; History, clinical or current evidence of any significant gastrointestinal, respiratory, hematological, metabolic, immunological or any other underlying disease which in the opinion of the investigator would interfere with the patient's participation in the trial; Hypersensitivity or contraindications to ARBs or ACE inhibitors or any cross allergy; Treatment with disallowed medication; Pregnant or breastfeeding females or females of childbearing potential without adequate contraception; History of drug and/or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>